-
Safety
Surveillance Study for Study Drug in the Treatment of Patients
with Depression.
-
Multicenter
Fixed Dose Study of Study Drug in Depressed Patient.
-
A
Double-Blind Placebo Controlled Fixed Dose Study of Study
Drug in Outpatients with Major Depressive Disorder.
-
Study
Drug vs. Placebo in the Treatment of Patients with Psychosis
Associated with Dementia of the Alzheimer's Type.
-
A
Phase III, Six Week, Double-Blind, Multicenter, Placebo-Controlled
Study Evaluating the
Efficacy and Safety of Three Fixed Doses of Study Drug and
Haloperidol in the Acute
Exacerbation of Schizophrenia and Schizoaffective Disorder.
-
A
Fifty-Two Week, Open-Label, Randomized Study Evaluating the
Safety and Efficacy of Study Drug and Risperidone (3-5 mg,
BID) in the Maintenance Treatment of Outpatients with
Schizophrenia and Schizoaffective Disorder.
-
A
Fifty-Two Week Open Extension Study Evaluating the Safety
and Outcome of Study Drug
Daily in the Treatment of Subjects who have Participated in
Previous Study Drug Clinical Trials. (Schizophrenia and Schizoaffective
Disorder)
-
A
156-Week (3-year) Open Extension Study Evaluating the Safety
and Outcome of Study Drug or 1-8 mg BID of Oral Risperidone
in the Treatment of Subjects who have Participated in Previous
Study Drug Clinical Trials. (Schizophrenia and Schizoaffective
Disorder)
-
A
260-Week (5-year) Open Extension Study Evaluating the Safety
and Outcome of Study Drug or 1-8 mg BID of Oral Risperidone
in the Treatment of Subjects who have Participated in Previous
Study Drug Clinical Trials. (Schizophrenia and Schizoaffective
Disorder)
-
Clinical
Evaluation of Efficacy and Safety of Study Drug in the Treatment
of Alzheimer's
Disease.
-
Safety
of Study Drug in the Long-Term Treatment of Alzheimer's Disease:
An Open Label
Extension Study.
